Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


MSD, Pfizer name new advisers

Posted 8 August 2019

MSD has finally found its new public affairs head, while both Novo and Pfizer have experienced shuffles in their communications teams in the latest job movements in the industry. 

MSD has appointed Luke Cornish as its new head of public affairs after former lead Scott McIntyre departed from the position in June

Cornish came into the role from within the company, where he was associate director business development Asia Pacific.

A long-time MSD employee, Cornish began his career at MSD in 2010 as a policy analyst after working in journalist and editor roles for market publications, according to his Linkedin profile. Other roles he held at MSD included those as a senior government relations manager and in external affairs. 

Meanwhile, Novo Nordisk is searching for a new public affairs lead after pharma stalwart and Pfizer's former head of communications Paul de Leon left the role following a three-month stint at the company.

De Leon has gone to health insurance company BUPA, where he will be head of corporate affairs in aged care and look after its Royal Commission work. 

Pfizer has also ended its search for a new communications manager, appointing Helen Han into the role. Han was formerly the senior manager media and corporate communications at icare NSW. 

Outside of industry NPS MedicineWise has appointed a new chair for its Choosing Wisely Australia Advisory Group.

The organisation named Dr David Rosengren, executive director and senior staff specialist emergency physician at the Royal Brisbane and Women's Hospital, in the position today. 

Ex-Gilead chief and Aussie OA heads biotech

Gilead's former global chief scientific officer and distinguished Australian doctor John McHutchison has been appointed the CEO of California biotechnology company Assembly Biosciences. 

The company announced the appointment earlier today after McHutchison left his senior post at Gilead last month. The Australian doctor helped develop a number of marketed therapies for hepatitis C and B in his nine years the company. 

The new move keeps with McHutchison's expertise, as Assembly is looking to develop new medicines for hepatitis B treatment with four candidates in clinical development.  

McHutchison received an Order of Australia in June 2018 for his work on developing hepatitis therapies. 

Yajun Ma

Pipeline Monitor
BMS I-Os target liver
Combo under priority review for HCC in US.
Top of the Hill
The pill or the cure
New gene therapies a challenge for payers.
Approvals Action
Novartis' newest drug
First-ever oral SPMS drug Mayzent arrives.